- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Antiviral drug remdesivir should not be used to treat Covid patients, warns WHO
Geneva: The World Health Organization (WHO) on Friday warned that the antiviral drug remdesivir should not be used to treat Covid-19 patients no matter how ill they are as there is no evidence it works.
"The panel found a lack of evidence that remdesivir improved outcomes that matter to patients such as reduced mortality, need for mechanical ventilation, time to clinical improvement, and others," Xinhua news agency quoted the WHO's Guideline Development Group (GDG) panel ass aying in a sattement .
"Any beneficial effects of remdesivir, if they do exist, are likely to be small and the possibility of important harm remains," the panel added.
The WHO recommendation, published in the British Medical Journal, was based on an evidence review that included data from four international randomised trials among more than 7,000 hospitalised patients.
After reviewing the evidence, the panel concluded that remdesivir has no meaningful effect on death rates or other important outcomes for patients.
"Especially given the costs and resource implications associated with remdesivir... The panel felt the responsibility should be on demonstrating evidence of efficacy, which is not established by the currently available data," it said.
The antiviral is one of only two medicines currently authorized to treat Covid-19 patients across the world.
It has been approval for use in the US, the European Union and other countries after initial research found it may shorten recovery time in some Covid-19 patients.
Made by the US company Gilead, remdesivir is extremely expensive and has to be given intravenously.
Gilead said last month that the drug had boosted its third quarter sales by about $900 million.
The WHO's warning comes as the overall number of global coronavirus cases has topped 56.8 million, while the deaths have surged to more than 1.35 million, according to the Johns Hopkins University.
In its latest update on Friday, the University's Center for Systems Science and Engineering (CSSE) revealed that the current global caseload and death toll stood at 56,817,667 and 1,358,489, respectively.
The US is the worst-hit country with the world's highest number of cases and deaths at 11,710,084 and 252,484, respectively, according to the CSSE.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.